GlassScriptPhysician profile
Krystal Peirce
NPI 1992201776
$1,316.37
in general payments reported to CMS, 2019-2025
21 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 96% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
See the full distribution for General Practice (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $137.17 | 2025 | Jardiance, Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.99 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $114.70 | 2025 | Rexulti |
| Abbvie INC. | $107.47 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.61 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $84.64 | 2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $84.51 | 2025 | |
| Neurocrine Biosciences, INC. | $71.92 | 2025 | |
| Lundbeck LLC | $66.60 | 2025 | Rexulti |
| Indivior INC. | $62.78 | 2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $50.45 | 2025 | Austedo Xr |
| Exact Sciences Corporation | $48.35 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $44.57 | 2025 | Korlym |
| Eisai INC. | $37.60 | 2025 | |
| Pfizer INC. | $36.37 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33.10 | 2025 | Ozempic |
| Baxter Healthcare | $27.72 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Alkermes, INC. | $27.42 | 2025 | Aristada, Lybalvi |
| Amgen INC. | $24.76 | 2025 | Repatha |
| Phathom Pharmaceuticals, INC. | $21.38 | 2025 | Voquezna |
| Medtronic, INC. | $18.26 | 2025 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Peirce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.